Patents Examined by Robert A. Wax
  • Patent number: 11026939
    Abstract: Solid pharmaceutical compositions with high drug loading are provided. A formulation useful for the solid pharmaceutical composition includes valbenazine, or a pharmaceutically acceptable salt thereof, silicified microcrystalline cellulose, isomalt, hydroxypropyl methylcellulose, partially pregelatinized maize starch, and magnesium stearate.
    Type: Grant
    Filed: October 19, 2020
    Date of Patent: June 8, 2021
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Richard Alexander Moore, Jr., Gregory A. McClelland, Christopher F. O{grave over ( )}Brien
  • Patent number: 11028348
    Abstract: Various aspects of the embodiments relate to methods of cleaning and disinfecting with a mixture comprising a cleaning and disinfecting composition concentrate and water. The cleaning and disinfecting composition concentrate typically comprises an organic acid, a surfactant, and an alcohol, and the concentrate typically lacks any halogenated molecule.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: June 8, 2021
    Assignee: ProNatural Brands, LLC
    Inventors: William Salminen, Gary M. Russotti, Richard Aab, Robert Tuchrelo, Jeffrey Cahoon
  • Patent number: 11026893
    Abstract: The present disclosure relates to a taste-masking microcapsule composition. The composition comprises a core portion encapsulated by a shell portion. The core portion comprises an active pharmaceutical ingredient (API) and one or more excipients. The shell portion comprises a hydrophobic matrix and a pH-responsive material. The microcapsule compositions prevent API release at the more neutral pH levels in the oral cavity, but upon exposure to pH levels of the stomach, the pH-responsive material becomes soluble thereby permitting release of the API.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: June 8, 2021
    Assignee: Adare Pharmaceuticals USA, Inc.
    Inventors: Cory Berkland, Milind Singh
  • Patent number: 11026886
    Abstract: Disclosed is a dry powder oral formulation that includes an active pharmaceutical ingredient (API), a lecithin powder, a galactomannan, one or more sweetening agents, one or more flavoring agents and an organic acid in a pharmaceutically acceptable preparation. Also disclosed are an excipient composition in absence of an API and methods of making and using the formulations and compositions. Also disclosed is a chewable, swallowable, and/or orally disintegrating tablet comprising an active pharmaceutical ingredient (API), a lecithin powder, a galactomannan, one or more sweetening agents, one or more flavoring agents and an organic acid in a pharmaceutically acceptable preparation.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: June 8, 2021
    Assignee: Marenda Pharmaceuticals LLC
    Inventors: Andrew Favara, Marc Karetny
  • Patent number: 11026444
    Abstract: The invention relates to a nutritional composition comprising a Human Milk Oligosaccharide (HMO) having an effect on the promoting, enhancement or improvement of the short term memory of the subjects in infants and/or young children. The composition can be an infant formula. The HMO may be 2FL, Di FL and/or LNT and or LNnT or combinations thereof.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: June 8, 2021
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Jian Yan, Jonas Hauser
  • Patent number: 11020377
    Abstract: Embodiments are directed to a secnidazole formulations and the use of a secnidazole formulation for the treatment of bacterial vaginosis (BV).
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: June 1, 2021
    Assignee: LUPIN INC.
    Inventors: Helen S. Pentikis, David Palling, Carol J. Braun
  • Patent number: 11020347
    Abstract: A self-foaming composition is described that includes trifarotene, for a no-rinse topical application and for application to the skin. The composition can include: at least one intermediate composition B including a gas-generating agent; at least one intermediate composition A including an agent for activating the gas-generating agent; and trifarotene or one of the pharmaceutically acceptable salts thereof being present in at least one of the intermediate compositions A and B. The composition is particularly intended for the treatment of acne. Also described is a kit or a single container including a plurality of compartments including such a composition.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: June 1, 2021
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Jean-Christophe Buge, Karine Nadau-Fourcade
  • Patent number: 11020348
    Abstract: A self-foaming composition is described that includes trifarotene, for a no-rinse topical application. The composition can include: at least one intermediate composition B including a gas-generating agent; at least one intermediate composition A including an agent for activating the gas-generating agent; and trifarotene or one of the pharmaceutically acceptable salts thereof being present in at least one of the intermediate compositions A and B. The composition is particularly intended for the treatment of ichthyosis. Also described, is a kit or a single container including a plurality of compartments including such a composition.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: June 1, 2021
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Jean-Christophe Buge, Karine Nadau-Fourcade
  • Patent number: 11013697
    Abstract: The present invention relates to a transdermal therapeutic system for administration of an active ingredient and a process for the preparation thereof. The transdermal therapeutic system comprises an overtape with two adhesive layers.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: May 25, 2021
    Assignee: Luye Pharma AG
    Inventors: Björn Schurad, Marieke Gosau
  • Patent number: 11013678
    Abstract: A skin care product is provided. The skin care product includes a multi-component skin care composition disposed in a multi-chamber container. The multi-component skin care composition includes an aqueous carrier component and a nicotinamide riboside component disposed in separate chambers, which prevents these components from contacting one another prior to use. The aqueous carrier component and the nicotinamide riboside component can be separated from one another by one or more fluid impermeable dividing members and/or activatable elements, which upon activation enable contact between the aqueous carrier component and nicotinamide riboside component.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: May 25, 2021
    Assignee: The Procter & Gamble Company
    Inventors: Tomohiro Hakozaki, John Erich Oblong, Jesus Velazquez
  • Patent number: 11013899
    Abstract: Embodiment provided herein are directed to microneedle patches for agent application on a mammal skin. The microneedle patch may comprise a patch scaffold having a surface, and a plurality of microneedles disposed on the surface. Each of the microneedles may be capable of piercing the skin 50 ?m to 1000 ?m deep, and comprises a composite material comprising polyvinylpyrrolidone (PVP) and one or more additional copolymers selected from the group consisting of maltose, leucine, and dileucine.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: May 25, 2021
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Mohamed R. Ahmed, Jayakumar Rajadas, Wenchao Sun, Mohammed Inayathullah Nazir Ahmed, Feng Xu
  • Patent number: 11007205
    Abstract: Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia, such as cinacalcet or a salt thereof, and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: May 18, 2021
    Assignee: EIRGEN PHARMA LTD.
    Inventors: P. Martin Petkovich, Joel Z. Melnick, Jay A. White, Samir P. Tabash, Charles W. Bishop, Susan Peers, Stephen A. Strugnell
  • Patent number: 11000476
    Abstract: A cavitation seed for drug delivery, and a drug delivery method using the same are disclosed. The cavitation seed according to the present invention comprises: a shell which forms the outer surface thereof to maintain the outer shape thereof within a fluid; and a core which is located inside the shell to determine buoyancy of the cavitation seed within the fluid. The cavitation seed can improve an effect of delivering a drug into a body since cavitation is induced by ultrasound at a position close to the epidermis. In addition, the cavitation seed can be applied in the delivery of various drugs as well as skin cosmetics, such as skin tone lightening agents, depilatories, hair restorers and skin fillers, skin analgesics, local anesthetics, agents for genetic diseases such as psoriasis, and agents for treatment of skin disease such as skin cancer.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: May 11, 2021
    Assignee: Pacific System Co., Ltd.
    Inventors: Jong Woo Seo, Jong Bum Seo, Gill Soo Song
  • Patent number: 11000508
    Abstract: Method of treating trichomoniasis in a subject in need thereof involving administering to the subject a therapeutically effective amount of secnidazole in a microgranule formulation, wherein the microgranule formulation comprises a plurality of microgranules having a volume-weighted particle size distribution within a microgranule population, wherein the volume-weighted particle size distribution as measured from a representative sample of the microgranule population comprises (a) at least 10% of the microgranule population having a volume-weighted particle size about no less than 470 micrometers; or (b) 50% of the microgranule population having a volume-weighted particle size between about no less than 640 micrometers and about no more than 810 micrometers; or (c) 90% of the microgranule population having a volume-weighted particle size about no more than 1170 micrometers; or (d) a combination thereof, which can include some or all of (a) through (c) above.
    Type: Grant
    Filed: June 15, 2020
    Date of Patent: May 11, 2021
    Assignee: LUPIN INC.
    Inventors: Helen S. Pentikis, David Palling, Carol J. Braun, Richard Holl
  • Patent number: 11004552
    Abstract: A method for creating a multi-antigen patch, comprising providing one or more transdermal patch sheets having a plurality of single dose transdermal patches residing thereon, wherein each one of the plurality of single dose transdermal patches includes an antigen at a particular dilution level disposed within a carrier, removing one or more of the plurality of single dose transdermal patches from the one or more transdermal patch sheets, adhering the one or more of the plurality of single dose transdermal patches to a backing, wherein the backing allows for multiple single dose transdermal patches to be adjacently adhered thereon, and covering the plurality of transdermal patches adhered to the backing with a peelable release liner.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: May 11, 2021
    Assignee: ROCA MEDICAL LTD.
    Inventors: James Strader, Jovan Hutton Pulitzer
  • Patent number: 11000507
    Abstract: Method of treating bacterial vaginosis in a subject in need thereof involving administering to the subject a therapeutically effective amount of secnidazole in a microgranule formulation, wherein the microgranule formulation comprises a plurality of microgranules having a volume-weighted particle size distribution within a microgranule population, wherein the volume-weighted particle size distribution as measured from a representative sample of the microgranule population comprises (a) at least 10% of the microgranule population having a volume-weighted particle size about no less than 470 micrometers; or (b) 50% of the microgranule population having a volume-weighted particle size between about no less than 640 micrometers and about no more than 810 micrometers; or (c) 90% of the microgranule population having a volume-weighted particle size about no more than 1170 micrometers; or (d) a combination thereof, which can include some or all of (a) through (c) above.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: May 11, 2021
    Assignee: LUPIN INC.
    Inventors: Helen S. Pentikis, David Palling, Carol J. Braun, Richard Holl
  • Patent number: 11000635
    Abstract: Disclosed are compositions comprised of Oxidized Cellulose (OC), such as oxidized regenerated cellulose (ORC), and an antibiotic comprised of minocycline, methods of preparation thereof and uses thereof.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: May 11, 2021
    Assignees: Omrix Biopharmaceuticals Ltd., Ethicon, Inc.
    Inventors: Eve Montia, Dwayne Looney, Theresa Scheuble, Ronen Eavri, Roi Mashiach
  • Patent number: 10993994
    Abstract: The present invention refers to nanoparticles comprising a core, said core comprising a non-crosslinked albumin matrix and a monoclonal antibody, optionally coated with a non-ionic polymer for use as a medicament, to a pharmaceutical composition comprising said nanoparticles, as well as their use in the treatment of cancer an ocular diseases.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: May 4, 2021
    Assignees: UNIVERSIDAD NACIONAL DE CÓRDOBA, CONSEJO NACIONAL DE INVESTIGACIONES CIENTÍFICAS Y TÉCNICAS, UNIVERSIDAD DE NAVARRA
    Inventors: Daniel Alberto Allemandi, Carolina Boiero, Juan Manuel Irache Garreta, Juan Manuel Llabot, Inés Luis De Redíin Subirá, Iván Peñuelas Sánchez, Gemma Quincoces Fernández
  • Patent number: 10993916
    Abstract: Crystalline microparticles consisting of a phenylalkylamino beta2-adrenergic agonist coated with a C12-C20 fatty acid are useful for the preparation of pharmaceutical aerosol formulations in form of suspension in a liquefied propellant gas or powder formulations.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: May 4, 2021
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Gaetano Brambilla, Paolo Colombo, Francesca Buttini, Michele Miozzi
  • Patent number: 10993961
    Abstract: The present invention concerns a dialysis acid precursor composition for use during preparation of a dialysis acid concentrate solution and for mixing with water and a bicarbonate containing concentrate into a ready-for-use dialysis solution. Said dialysis acid precursor composition consist of powder components comprising sodium chloride, at least one dry acid and at least one magnesium salt, and optionally potassium salt, calcium salt, and glucose. According to the invention said at least one magnesium salt and said optional glucose, are present as anhydrous components in said dialysis acid precursor composition.
    Type: Grant
    Filed: June 20, 2011
    Date of Patent: May 4, 2021
    Assignee: Gambro Lundia AB
    Inventors: Ola Carlsson, Torbjorn Linden, Lennart Jonsson, Anders Wieslander